2026-ASCO-A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a phase II study presented at 2026-ASCO-A, which investigates the efficacy of a combination therapy involving FOLFIRINOX, elraglusib, and losartan in patients with untreated metastatic pancreatic ductal adenocarcinoma. This research aims to assess the potential benefits of these agents in improving treatment outcomes for this challenging cancer type.
Price reaction · baseline $2.02 (2026-05-29 close) · 1 other ACTU headline(s) in the window, move may be shared
day 0 close
-1.5%
day 1
-6.9%
day 3
-4%
Market Sentiment Analysis
POSITIVE FACTORS
The study explores a novel combination therapy for mPDAC.
Involves well-known agents like FOLFIRINOX, elraglusib, and losartan.
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
9.4%
average across 4 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
9-ING-41
Phase 2 · Cancer
Full Press Release Details
2026-ASCO-A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) Download PDF View Resource
Frequently Asked Questions
What is the focus of the 2026-ASCO-A study?
The study focuses on a phase II trial combining FOLFIRINOX, elraglusib, and losartan for mPDAC.
What type of cancer is being targeted in this study?
The study targets untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
What agents are included in the combination therapy?
The combination therapy includes FOLFIRINOX, elraglusib, and losartan.